Charles Bisgaier, PhD
Dr. Charles Bisgaier is an entrepreneur and biochemist and has been involved in a variety of successful commercial businesses including early-stage start-ups, and later stage private and public entities. He has been involved with the discovery, research and development of a number of commercial pharmaceuticals including LOPID® (gemfibrozil), LIPITOR® (Atorvastatin), NEXLETOL® (Bempedoic Acid) and with the dNAV® medical device. He is still actively involved in the late-stage development of GEMCABENE, and for the new clinical candidates DT-678 (Anti-platelet Therapy), DT-109 (For NASH), BF-844 (for Usher Syndrome 3A), yeast platform protein expression systems for vaccine development and diagnostic tools and next generation CRISPR/Cas 9 gene editing technologies for treatment of rare genetic disease include eye diseases and cystic fibrosis. He has served in management and board positions at a number of public and private companies and non-profit organizations throughout his career, including Parke-Davis/Warner-Lambert, Pfizer, Esperion Therapeutics, ProNAi Therapeutics, Pipex Pharmaceuticals, Gemphire Therapeutics, Hygieia Inc, BioSavita, Diapin Therapeutics, GeneToBe, Imagine Pharma, the Usher III Initiative and the Michigan Society for Medical Research. He has published over 100 scientific papers and inventions. He received a B.A. in biology from the State University of New York at Oneonta and an M.S. and Ph.D. in biochemistry from George Washington University. After receiving his Ph.D., he studied lipoprotein metabolism within the Specialized Center of Research for atherosclerosis at Columbia University College of Physicians and Surgeons.